Literature DB >> 9144903

New approaches in the use of radiation therapy in the treatment of infiltrative transitional-cell cancer of the bladder.

P Warde1, M K Gospodarowicz.   

Abstract

Organ preservation using primary radical radiation therapy (RT) is a viable treatment option for many patients with invasive bladder cancer, and there is no evidence that survival is compromised by this approach. However, the survival and local control rates in patients with bladder cancer currently treated with radical RT are not optimal. Combined modality therapy, altered radiation-fractionation approaches, and exciting new approaches such as the application of gene therapy and the use of hypoxic cell sensitisers, among others, may well improve the results of treatment in the future. Ongoing clinical research, including prospective randomised trials, will be required to evaluate these new approaches to therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9144903     DOI: 10.1007/bf02201984

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  55 in total

Review 1.  Radio-chemotherapy for invasive carcinoma of the bladder.

Authors:  W U Shipley; D S Kaufman; P Griffin; A F Althausen; N M Heney; G R Prout
Journal:  Front Radiat Ther Oncol       Date:  1992

Review 2.  The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy.

Authors:  R G Bristow; S Benchimol; R P Hill
Journal:  Radiother Oncol       Date:  1996-09       Impact factor: 6.280

3.  The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy.

Authors:  W Duncan; P M Quilty
Journal:  Radiother Oncol       Date:  1986-12       Impact factor: 6.280

Review 4.  Treatment of cancer with radiation and drugs.

Authors:  I F Tannock
Journal:  J Clin Oncol       Date:  1996-12       Impact factor: 44.544

5.  T3 bladder cancer--the case for salvage cystectomy.

Authors:  J P Blandy; H R England; S J Evans; H F Hope-Stone; G M Mair; B S Mantell; R T Oliver; A M Paris; R A Risdon
Journal:  Br J Urol       Date:  1980-12

6.  Predicting the outcome of radical radiotherapy for invasive bladder cancer.

Authors:  J A Vale; R P A'Hern; K Liu; W F Hendry; H N Whitfield; P N Plowman; C Sowter; G Slavin
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

7.  Organ-sparing treatment of advanced bladder cancer: a 10-year experience.

Authors:  J Dunst; R Sauer; K M Schrott; R Kühn; C Wittekind; A Altendorf-Hofmann
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-09-30       Impact factor: 7.038

8.  Bladder conservation in selected T1G3 and muscle-invasive T2-T3a bladder carcinoma using combination therapy of surgery and iridium-192 implantation.

Authors:  L M Moonen; S Horenblas; J C van der Voet; M J Nuyten; H Bartelink
Journal:  Br J Urol       Date:  1994-09

9.  Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients.

Authors:  A Pollack; G K Zagars; C P Dinney; D A Swanson; A C von Eschenbach
Journal:  Cancer       Date:  1994-11-15       Impact factor: 6.860

Review 10.  What to do if the lymph nodes are positive.

Authors:  C P Evans; D A Swanson
Journal:  Semin Urol Oncol       Date:  1996-05
View more
  1 in total

1.  Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

Authors:  Edmund Chiong; I-Ling Lee; Ali Dadbin; Anita L Sabichi; Loleta Harris; Diana Urbauer; David J McConkey; Rian J Dickstein; Tiewei Cheng; H Barton Grossman
Journal:  Clin Cancer Res       Date:  2011-03-17       Impact factor: 12.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.